Last reviewed · How we verify

NCT07160777: SEMDERMA

Performance and Safety of Semical Dermal Fillers in Facial Rejuvenation

Active, enrolled Last updated 8 September 2025
What this trial tests

trial testing cross-linked hyaluronic acid in Facial Aging in 80 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 November 2024
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorSemikal Technology
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment80
Start date1 November 2024
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Semikal Technology

Who can join

18 and older, any sex, with Facial Aging or Skin Rejuvenation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to verify safety and performance of Semical dermal fillers according to real-world data.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of cross-linked hyaluronic acid

Trials testing the same drug.

Other recruiting trials for Facial Aging

Currently open trials in the same condition.

Other Semikal Technology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07160777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing